← Eichor
Condition: Bladder Cancer Stage I Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Bladder Cancer Stage I

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05126472To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients Wi
Phase 1/Phase 2 · 6 location(s) · RemeGen Co., Ltd. · NCT06378242Sacituzumab Govitecan Plus EV in Metastatic UC
Phase 1/Phase 2 · 1 location(s) · Dana-Farber Cancer Institute · NCT04724018Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Phase 1/Phase 2 · 2 location(s) · University of Arizona · NCT06814496Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Phase 1 · 1 location(s) · Emory University · NCT04878029Can Second Resection for pT1 Bladder Cancer be Avoided After Initial En-Bloc Resection With Negative Safety Margins
Phase N/A · 1 location(s) · Mansoura University · NCT05969964A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC
Phase 1/Phase 2 · 1 location(s) · Shanghai Hengrui Pharmaceutical Co., Ltd. · NCT05410730Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT04235777A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle
Phase 1 · 1 location(s) · Shanghai Hengrui Pharmaceutical Co., Ltd. · NCT06108492To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With H
Phase 1 · 2 location(s) · Shenzhen Xinhe Biomedical · NCT07594964A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and U
NA · 1 location(s) · University of Washington · NCT06040762Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Amon
NA · 1 location(s) · University of Washington · NCT07302230A Phase I Intravesical PPM Therapy for NMIBC
Phase 1 · 1 location(s) · VA Office of Research and Development · NCT05519241Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer
Phase 1/Phase 2 · 1 location(s) · University of Texas Southwestern Medical Center · NCT06394570A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscl
Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT06733363PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bl
Phase 1 · 1 location(s) · University of California, Davis · NCT06173349Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
Phase 1/Phase 2 · 6 location(s) · Zhuhai Beihai Biotech Co., Ltd · NCT06732531A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer
Phase 1/Phase 2 · 12 location(s) · Suzhou Forlong Biotechnology Co., Ltd · NCT07122414Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
Phase 1 · 1 location(s) · Abramson Cancer Center at Penn Medicine · NCT06586255Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT06167356In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT06704191Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Phase 1/Phase 2 · 1 location(s) · Hadassah Medical Organization · NCT05296564Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Phase 1 · 1 location(s) · Baylor College of Medicine · NCT03740256Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Inva
Phase 3 · 58 location(s) · Alliance for Clinical Trials in Oncology · NCT07000084Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Phase N/A · 745 location(s) · Alliance for Clinical Trials in Oncology · NCT05334069A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced
Phase 1/Phase 2 · 16 location(s) · BioNTech SE · NCT07186842HTL0039732 in Participants With Advanced Solid Tumours
Phase 1/Phase 2 · 5 location(s) · Cancer Research UK · NCT05944237Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy T
Phase 2 · 134 location(s) · National Cancer Institute (NCI) · NCT06770582Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
Phase 1 · 4 location(s) · Novartis Pharmaceuticals · NCT07660055IDOV-Immune for Advanced Solid Tumors
Phase 1 · 5 location(s) · ViroMissile, Inc. · NCT06910657
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.